PLUR (Pluri) Earnings per share for the last four quarters

Pluri Inc (PLUR) - corporate logo

Pluri Inc. previously reduced its reliance on clinical trials by redistributing platform resources. The EPS YoY TTM growth value demonstrates current profit dynamics, where the status is 13.80. Looking ahead, Pluri Inc. plans to develop its CDMO service to protect patents and integrate cell technologies into cultured meat production, merging medicine with foodtech.

PLUR pluri-biotech.com Net earnings per share (EPS TTM) (02/11/2024 - 11/16/2026)

PLUR (pluri-biotech.com): analytical breakdowns and indicator data

- business market valuation indicators:
Fundamental company valuation:PLUR (Pluri Inc)
Core merchandise of Pluri Inc.

Investors utilize this tool for asset stress-testing, analyzing the rolling annual trend of net income per share to filter out random market noise. The annual EPS growth rate over the last 12 months reflects the efficiency of Pluri Inc. (PLUR) biomedical capacities and the readiness of production zones for therapy, allowing for a real-time assessment of business capitalization through the lens of sustainable earnings growth.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS